Lakefront Biotherapeutics (GLPGF) EBIT Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBIT Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.59 Bn | 197.60 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 181.18 Bn | 178.00 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.46 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 61.66 Bn | 56.47 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 33.95 Bn | 30.64 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 31.27 Bn | 29.98 Bn | 1.96 Bn | -563.67% |
| 9 | Roivant Sciences | 29.82 Bn | 29.82 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | 21.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.63% |
| Mar 31, 2026 | 55.33% |
| Dec 31, 2025 | 1,056.85% |
| Sep 30, 2025 | -35.30% |
| Jun 30, 2025 | -159.06% |
| Mar 31, 2025 | -363.83% |
| Dec 31, 2024 | -67.41% |
| Sep 30, 2024 | -1,276.11% |
| Jun 30, 2024 | 842.89% |
| Mar 31, 2024 | -136.18% |
| Dec 31, 2023 | 5,629.05% |
| Sep 30, 2023 | 59.13% |
| Jun 30, 2023 | 81.95% |
| Mar 31, 2023 | 35.79% |
| Dec 31, 2022 | -13.66% |
| Sep 30, 2022 | 81.72% |
| Jun 30, 2022 | -44.71% |
| Mar 31, 2022 | 61.27% |
| Dec 31, 2021 | 102.22% |
| Sep 30, 2021 | -5.78% |